VAKCINA

The World Health Organization is warning that Africa will receive 25% fewer coronavirus vaccine doses than expected by the year's end — in part because of the approval of booster shots in developed countries.

https://t.co/UCQHXioqlw

— Axios (@axios) September 9, 2021

COVAX recently delivered five million vaccine doses to Africa, but 15 million doses have been thrown away in the United States since March, according to the head of the WHO in Africa.https://t.co/mfbfTdOOh1

— Forbes Science (@ForbesScience) September 9, 2021

Responding to Wednesday's announcement that the United Nations-backed COVAX program has again been forced to reduce its delivery projections, Matshidiso Moeti, the WHO's Africa Director, said the goal of vaccinating 10% of people in Africa by the end of September is no longer a realistic target. 
...
She noted that the vaccination rate in sub-Saharan Africa is just 1.7% and stated, "if companies and countries prioritize vaccine equity, this pandemic would be over quickly." 

Healthy boys may be more likely to be admitted to hospital with a rare side-effect of the Pfizer/BioNTech Covid vaccine that causes inflammation of the heart than with Covid itself, US researchers claim.
Their analysis of medical data suggests that boys aged 12 to 15, with no underlying medical conditions, are four to six times more likely to be diagnosed with vaccine-related myocarditis than ending up in hospital with Covid over a four-month period.

 In the latest study, which has yet to be peer reviewed, Dr Tracy Høeg at the University of California and colleagues analysed adverse reactions to Covid vaccines in US children aged 12 to 17 during the first six months of 2021. They estimate the rate of myocarditis after two shots of Pfizer/BioNTech vaccine to be 162.2 cases per million for healthy boys aged 12 to 15 and 94 cases per million for healthy boys aged 16 to 17. The equivalent rates for girls were 13.4 and 13 cases per million, respectively. At current US infection rates, the risk of a healthy adolescent being taken to hospital with Covid in the next 120 days is about 44 per million, they said.

The UK is preparing to become the first big country to administer “mix and match” coronavirus vaccines for its booster programme, according to senior government figures.
Many Britons are expected to have a third, booster dose that is different to their first two jabs, on the basis that it would provide better protection against Covid-19, said the government insiders.

Ministers want to press ahead with an autumn booster campaign after separate studies from Oxford university and the team behind the Zoe Covid app found that the protection against symptomatic infection provided by the BioNTech/Pfizer and the Oxford/AstraZeneca vaccines waned four to six months after second doses. 
...
Previous research has suggested benefits in mixing and matching vaccines. An Oxford university study, published in June, showed people who received a first jab of AstraZeneca followed by a second of Pfizer experienced a nine-fold increase in antibody levels compared with those who had two doses of AstraZeneca. 
...
One senior Department of Health insider said: “We’ll be giving Pfizer to those who had AstraZeneca the first time, and AstraZeneca to those who had Pfizer. It’s the best combination to get as much protection as possible.” Another senior Whitehall official confirmed that mixing doses was “how we’re going to do the autumn booster programme”.

Broj doza: 6.089.871 – prva doza 2.960.217, druga doza 2.832.387, treća doza 297.267
Državljani RS – prva doza 2.793.709, druga doza 2.684.746, treća doza 296.152
Strani državljani sa boravkom u RS – prva doza 9.669, druga doza 8.982, treća doza 476
Strani državljani bez boravka u RS – prva doza 156.839, druga doza 138.659, treća doza 639
ažurirano 09.09.2021

Broj doza: 5.882.966 – prva doza 2.923.123, druga doza 2.804.423, treća doza 155.420
Državljani RS – prva doza 2.757.999, druga doza 2.658.622, treća doza 154.940
Strani državljani sa boravkom u RS – prva doza 9.489, druga doza 8.821, treća doza 180
Strani državljani bez boravka u RS – prva doza 155.635, druga doza 136.960, treća doza 300
ažurirano 30.08.2021

Datih doza (svih): 21.538
Datih prvih doza: 3203
Datih drugih doza: 2686
Datih trećih doza: 15.650

bemty wrote:Boys more at risk from Pfizer jab side-effect than Covid, suggests study

Healthy boys may be more likely to be admitted to hospital with a rare side-effect of the Pfizer/BioNTech Covid vaccine that causes inflammation of the heart than with Covid itself, US researchers claim.
Their analysis of medical data suggests that boys aged 12 to 15, with no underlying medical conditions, are four to six times more likely to be diagnosed with vaccine-related myocarditis than ending up in hospital with Covid over a four-month period.

jedan moj drug pedijatar intenzivista stalno prica o ovome poslednjih meseci - kako su safety podaci zasnovani na tri hiljade dece, kako to nije dovoljno da se proceni da li su retki problemi cesci nego problemi izazvani kovidom, i kako bi bilo pametnije masovno slati zaliha vakcina zemljama gde ih nema dovoljno. zelela sam da nije u pravu i da vakcine budu prava stvar i za decu, posebno u zemljama gde se odrasli dvoume. 

doduse nije jos peer reviewed, a cekamo i podatke iz danske i drugih zemalja koje vakcinisu decu.

 In the latest study, which has yet to be peer reviewed, Dr Tracy Høeg at the University of California and colleagues analysed adverse reactions to Covid vaccines in US children aged 12 to 17 during the first six months of 2021. They estimate the rate of myocarditis after two shots of Pfizer/BioNTech vaccine to be 162.2 cases per million for healthy boys aged 12 to 15 and 94 cases per million for healthy boys aged 16 to 17. The equivalent rates for girls were 13.4 and 13 cases per million, respectively. At current US infection rates, the risk of a healthy adolescent being taken to hospital with Covid in the next 120 days is about 44 per million, they said.

Ferenc Puskás wrote:Nakon koliko vremena od primanja 2. doze se razvija upala srčanog mišića, u kojem vremenskom rasponu?